目的 研究消癌平口服液聯(lián)合貝伐珠單抗注射液治療中晚期非小細胞肺癌的臨床療效。方法 選取2016年1月—2019年1月河南大學第一附屬醫(yī)院收治的128例中晚期非小細胞肺癌患者，將所有患者隨機分為對照組和治療組，每組各64例。患者入院后均給予TC方案（卡鉑+紫杉醇）基礎治療，對照組患者第1天靜脈滴注貝伐珠單抗注射液，7.5 mg/kg；治療組患者在對照組基礎上口服消癌平口服液，10 mL/次，3次/d。21 d為1個療程，兩組患者持續(xù)治療4個療程。觀察兩組的臨床療效，比較兩組的血清癌胚抗原（CEA）、神經特異性烯醇化酶（NSE）、糖類抗原125（CA125）水平、Karnofsky（KPS）評分、無進展生存時間（PFS）、總生存時間（OS）和不良反應發(fā)生情況。結果 治療后，治療組疾病控制率（DCR）（78.12% vs 67.19%）和客觀緩解率（ORR）（64.06%vs 51.56%）顯著高于對照組（P<0.05）。治療后，兩組患者血清CA125、CEA、NSE水平顯著降低（P<0.05）；并且治療組血清CA125、CEA、NSE水平降低較多（P<0.05）。治療后，兩組患者KPS評分顯著升高（P<0.05）；并且治療組KPS評分升高較多（P<0.05）。治療后，治療組患者OS和PFS顯著高于對照組（P<0.05）。治療過程中，治療組胃腸道反應、血小板降低、白細胞降低和肝功能異常發(fā)生顯著低于對照組（P<0.05）。結論 消癌平口服液聯(lián)合貝伐珠單抗注射液治療中晚期非小細胞肺癌具有較好的治療效果，能夠提高患者生活質量，降低血清腫瘤標志物水平，值得在臨床上推廣應用。

Objective To study the clinical efficacy of Xiaoaiping Oral Liquid combined with Bevacizumab Injection in treatment of advanced non-small cell lung cancer. Methods Patients (128 cases) with advanced non-small cell lung cancer in the First Affiliated Hospital of Henan University from January 2016 to January 2019 were randomly divided into control and treatment groups, and each group had 64 cases. Patients were treated with TC regimen (carboplatin + paclitaxel). Patients in the control group were iv administered with Bevacizumab Injection at the first day, 7.5 mg/kg. Patients in the treatment group were po administered with Xiaoaiping Oral Liquid on the basis of the control group, 10 mL/time, three times daily. A course had 21 days, and patients in two groups were treated for 4 courses. After treatment, the clinical efficacies were evaluated, and serum levels of CEA, NSE, and CA125, KPS score, progression-free survival time (PFS), total survival time (OS), and adverse reactions were compared between two groups. Results After treatment, DCR (78.12% vs 67.19%) and ORR (64.06% vs 51.56%) in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum levels of CEA, NSE and CA125 in the two groups were significantly reduced (P<0.05). And the tumor markers in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, KPS scores in two groups were significantly decreased (P<0.05), and the KPS score in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, PFS and OS in the treatment group were significantly higher than those in the control group (P<0.05). The incidence of gastrointestinal reaction, thrombocytopenia, leukopenia and liver dysfunction in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Xiaoaiping Oral Liquid combined with Bevacizumab Injection has clinical curative effect in treatment of advanced non-small cell lung cancer, can improve the quality of life of patients and reduce the serum levels of tumor markers, which is worthy of clinical application.

R977

開封市科技發(fā)展計劃項目（1806005）